Safety, Tolerability and Efficacy of anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Rejection after Kidney Transplantation - A Pilot Trial
Latest Information Update: 23 Aug 2022
At a glance
- Drugs Clazakizumab (Primary)
- Indications Renal transplant rejection
- Focus Adverse reactions
- 15 Aug 2022 Results assessing the safety and efficacy of the anti-IL-6 monoclonal antibody clazakizumab in late antibody-mediated rejection published in the Transplantation
- 06 Sep 2020 Status changed from active, no longer recruiting to completed.
- 06 Aug 2020 This trial has been completed in Austria, according to European Clinical Trials Database record.